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A B S T R A C T
Objective: To determine herpes simplex virus (HSV)-2 and HSV-1 seroprevalence in women and men in
Romania.
Methods: A cross-sectional seroprevalence survey was conducted between 2004 and 2005 on a total of
1058 women and men representative of the population of Bucharest. All participants were aged 15–44
years and completed a structured questionnaire. A blood sample was collected to detect IgG anti-HSV-1
and HSV-2 serum antibodies using the HerpeSelect ELISA (Focus Diagnostics).
Results: A total of 761 women (median age 29 years) and 297 men (median age 29 years) were included.
Overall, HSV-2 seroprevalence (15.2%) increased with age. Among women, HSV-2 seroprevalence
increased from 11.0% in 15–19-year-olds to 38.3% in 40–44-year-olds. Among men, seroprevalence
increased from 4.0% in 20–24-year-olds to 27.1% in 40–44-year-olds. HSV-2 seroprevalence was
signiﬁcantly higher among women than men (17.0% vs. 10.8%). HSV-1 seropositivity was high (87.2%) in
all age groups, with no clear trend by age or by sex. In addition to older age and female sex, risk factors for
HSV-2 included greater number of lifetime sexual partners, lower educational attainment, and history of
genital vesicles. Lower educational level and rural residence were associated with a higher risk of HSV-1
seropositivity.
Conclusions: In Romania, HSV-2 seroprevalence was higher in women than men, and was within
European limits and lower than that in Africa and the USA. In contrast, HSV-1 seroprevalence was
generally higher than that previously recorded in similarly aged populations in Western Europe.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Herpes simplex virus type-2 (HSV-2) infection is endemic in
many geographical areas1 and associatedwith a higher risk of HIV
infection.2,3 As one of the most prevalent sexually transmitted
infections (STIs)worldwide,4HSV-2 is theprimary causeof genital
ulcerations in both developed and developing countries.5 HSV-2
and HSV-1 are alpha-herpes viruses which share approximately
50% nucleotide sequence homology6,7 and can infect both
orolabial and anogenital sites. Genital lesions induced by these
two herpetic viruses are clinically indistinguishable. Classically,
HSV-2 is characterized by anogenital infection, whereas HSV-1 is* Corresponding author. Tel.: +1 919 966 7450; fax: +1 919 966 2089.
E-mail address: jennifers@unc.edu (J.S. Smith).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.07.026associated with orolabial infections. Over the past decade, a
higher proportion of genital herpes has been attributed to HSV-1
in several world regions,8,9 likely due to changes in sexual
behavior and in the incidence of orolabial HSV-1 infection
acquired during childhood.
As both HSV-2 and HSV-1 infections are generally asymptom-
atic,10 estimations of their population-based seroprevalence are
most reliably made by determining type-speciﬁc IgG HSV-2 and
HSV-1 seropositivity.8 The seroprevalence of HSV-2 and HSV-1
vary considerably by continent, with seropositivity clearly being
dependent upon age.1 There are certain geographical regions,
however, with limited or no data on type-speciﬁc HSV seropreva-
lence, notably in Central and Eastern Europe. Further, only a few
studies have reported differences in the seroprevalence and risk
factors for HSV-2 seropositivity for women vs. men.ses. Published by Elsevier Ltd. All rights reserved.
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seroprevalence using validated type-speciﬁc serological assays in
Bucharest, Romania, an ex-communist country with a population
of 21 million.11 To determine the burden of HSV-2 and HSV-1
infection in Bucharest, we conducted a study to estimate type-
speciﬁc HSV-1 and HSV-2 seroprevalence and to identify
associated HSV-2 risk factors, stratiﬁed by sex.
2. Materials and methods
2.1. Population surveyed
Between January 2004 and June 2005, an HSV seroprevalence
survey was conducted among 1066 hospital attendees in
Bucharest, Romania. Study participants were eligible if they
were over 15 years of age and permanent residents of Bucharest.
We excluded those patients who, at the time of enrollment in
the study, had labial and genital herpes (recurrent or not),
varicella, herpes zoster, viral encephalitis, a symptomatic
sexually transmitted disease (STD; genital ulcerative disease,
dysuria, genital discharge, genital warts), AIDS, or a severe
mental disorder. Symptomatic HIV infection was deﬁned by
known HIV infection at stage B or C of the Centers for Disease
Control and Prevention (CDC) classiﬁcation. The study was
approved by the ethical review committees of the two
participating hospitals.
Study participants were selected from two different popula-
tions. The ﬁrst population, consisting of 452 pregnant women aged
15–39 years, was recruited during prenatal visits to the Elias
University Emergency Hospital. The second population group
included 606 patients (297men and 309women) aged between 15
and 44 years attending the Professor Dr. Matei Bals National
Infectious Diseases Institute. The present analysis includes HSV-2
type-speciﬁc data on a subset of 452 pregnant women. In both
populations, sampling was conducted within stratiﬁed age groups
of ﬁve-years to include approximately equal sample sizes per ﬁve-
year age group (15–19, 20–24 years, etc.), stratiﬁed by sex. Both
Bucharest hospitals have university staff and catchment areas
including all parts of Bucharest. Of the total eligible subjects, 90% of
the women and 84% of the men participated.
2.2. Questionnaire and laboratory testing
After obtaining informed consent, each participant completed
an anonymous standardized questionnaire to collect information
on sociodemographics, sexual behavior, reproductive and gyneco-
logical history, family planning, and smoking habits. During
clinical examination, a 5-ml blood sample was collected for the
detection of antibodies to HSV-1 and HSV-2. Collected samples
were centrifuged at 1000 g for 10 min. Serum samples were
transferred to sterile cryotubes of 0.5–1 ml, stored at 70 8C, andTable 1
HSV-2 and HSV-1 seroprevalence in Bucharest, Romania, in the total population and b
Total sample
Sample size 1058
Median age in years (range) 29 (15–44)
HSV-2 (%) 15.2
HSV-1 (%) 87.2
Both HSV-1 and HSV-2 positive (%) 12.9
Both HSV-1 and HSV-2 negative (%) 10.5
Genital herpes history in HSV-2 positives (%) 23.0
Oral herpes history in HSV-1 positives (%) 63.1
HSV, herpes simplex virus.
a By Mantel–Haenszel test between males and females.
b By Pearson Chi-square test between males and females.processed in the laboratory at the Professor Dr. Matei Bals National
Infectious Diseases Institute.
Type-speciﬁc serum antibodies to HSV-1 and HSV-2 were
detected using HerpeSelect 1 and HerpeSelect 2 IgG ELISAs (Focus
Diagnostics, Cypress, CA, USA), as per the manufacturer’s instruc-
tions. The HerpeSelect HSV serological tests are based on
glycoprotein G antigens to elicit type-speciﬁc antibody responses:
gG1 from HSV-1 and gG2 from HSV-2. In accordance with the
manufacturer’s instructions, an optical density cut-off value of 1.1
was used to deﬁne HSV-1 and HSV-2 seropositivity. In terms of the
speciﬁed cut-off point for the HerpeSelect HSV-2 ELISA to deﬁne
HSV-2 seropositivity, we chose not to use the modiﬁed higher cut-
off value of >3.5, as we have found that this cut-off does not
necessarily result in optimal performance (largely due to inade-
quate sensitivity) based on a validation study in Kenya.12 Equivocal
samples were retested using the same ELISA test. In total, four
samples were equivocal for HSV-1 and four samples for HSV-2. All
eight samples remained equivocal after retesting and were
excluded from statistical analyses. All samples were tested blinded
of the original questionnaire results.
For quality control purposes, a total of 74 samples (7%) were
retested in a blinded fashion with the HerpeSelect HSV-1 and HSV-
2 ELISAs (Focus Diagnostics). For all samples, the retest results
agreedwith the original test for both HSV viral types. Type-speciﬁc
HSV test results were not systematically reported back to the study
participants, given that treatment based on HSV serostatus is not
currently the recommended standard of care.
2.3. Statistical analyses
A Mantel–Haenszel Chi-square test was used to determine
differences in HSV-1 and HSV-2 seroprevalence. To evaluate risk
factors for type-speciﬁc HSV-2 seropositivity, odds ratios (OR) and
95% conﬁdence intervals (95% CI) were calculated by multiple
logistic regression, controlling for age, study site and, if appropri-
ate, sex, using SPSS v. 12.0 (SPSS Inc., Chicago, IL, USA). A similar
analysis was performed for HSV-1 infection. Data were combined
for pregnant and non-pregnant women because demographic
characteristics including age were comparable between the two
groups. Tests for trend for odds ratioswere assessed by considering
the categorical variable as a continuous variable in the logistic
model. A multiple logistic regression model was ﬁtted by starting
with a model containing all variables considered to be predictive
for HSV-2 infection and proceeding by backward selection.
3. Results
Type-speciﬁc HSV serological results were available for 1058
patients (761 females, 297 males), with a median age for both
sexes of 29 (range 15–44) years (Table 1). Overall, HSV-2
seroprevalence was 15.2%, with seroprevalence among womeny sex
Females Males p-Value
761 297
29 (15–44) 29 (15–44)
17.0 10.8 0.016a
88.0 85.2 0.251a
14.7 8.4 0.015b
9.7 12.5 0.015b
21.7 28.1 0.129a
64.8 58.5 0.768a
V. Arama et al. / International Journal of Infectious Diseases 14S (2010) e25–e31 e27(17.0%) higher than men (10.8%). HSV-1 seroprevalence was 87.2%
overall, and similar among women (88.0%) and men (85.2%). Dual
seropositivity was present in 12.9% of samples (females 14.7%,
males 8.4%), while 10.5% of the overall study samples had no
antibodies for either subtype (females 9.7%,males 12.5%). A history
of genital herpes in HSV-2 positive participants was less common
(23.0% symptomatic genital herpes in the HSV-2 seropositive
group) than a history of oral herpes in the HSV-1 positive
participants (63.1%).
HSV-2 seroprevalence gradually increased with age to peak at
the oldest age surveyed of 40–44 years of age for both sexes
(Figure 1A). Among women, HSV-2 seroprevalence increased from
11.0% in those aged 15–19 years to 38.3% in those aged 40–44
years; among men it increased from 4.0% in 20–24-year-olds to
27.1% in 40–44-year-olds. There was little variation across age
groups for HSV-1, reﬂective of the high seroprevalence (80%) for
all age groups (Figure 1B). For both serotypes, the seroprevalence
in males was consistently lower than that in females, with the one
exception of HSV-1 in the 35–39 years age group.
In univariate analyses, the strongest risk factors for HSV-2
seropositivity among all participants in the age-, center-, and sex-
adjusted model (Table 2) included age (OR 6.6, 95% CI 3.3–13.0 for
40–44 vs. 20–24 years) and history of genital herpes (OR 7.1, 95% CI
4.2–12.1 vs. without history of genital herpes). Additional risk
factors included the total number of sex partners (OR 3.5, 95% CI
2.1–5.9 for 3+ vs. 0–1), number of occasional sex partners, deﬁned
by persons with whom the subject had a rare, irregular sexual
relationship, for less than 6 months (OR 1.9, 95% CI 1.1–3.3 for 3+
vs. none), reporting lower educational attainment (OR 2.3, 95% CI
1.2–4.6 for primary education vs. higher education), age at ﬁrst
intercourse (OR 2.6, 95% CI 1.3–5.1 for age 16 vs. 21 years), and
any STI history (OR 2.1, 95% CI 1.3–3.1). Other potential risk factors
that were not associated with overall HSV-2 seropositivity in the
combined study population included smoking status and ever use
condoms. HSV-2 risk factors were generally similar between
women and men, although speciﬁc associations for women
appeared stronger than those for men: lower educational
attainment (OR 2.9, 95% CI 1.3–6.5 for primary vs. higher),
reporting two lifetime sexual partners (OR 2.2, 95% CI 1.4–3.5 vs.
0–1), having had three or more occasional sexual partners (OR 2.5,
95% CI 1.2–5.2), age at ﬁrst intercourse 16 years (OR 2.6, 95% CI
1.1–6.0), and any STI history (OR 1.88, 95% CI 1.2–3.0).
Overall HSV-1 seropositivity among all study participants in the
age-, center-, and sex-adjusted model was associated with lowerFigure 1. Seroprevalence of (A) HSV-2 and (B) HSV-1, by sex and age, Romania.educational attainment (OR 2.3, 95% CI 1.1–4.9 for primary
education vs. higher education), being born in rural areas (OR
2.4, 95% CI 1.3–4.5 vs. urban), younger age at ﬁrst intercourse (OR
3.0, 95% CI 1.4–6.5 for 16 vs. 21 years), and a greater number of
sexual partners (OR 2.1, 95% CI 1.2–3.7 for 3+ vs. 1 sex partner)
(Table 3). HSV-1 risk factors in women included lower education
(OR 2.8, 95% CI 1.6–4.6 for secondary vs. higher) and rural place of
birth (OR 2.4, 95% CI 1.1–5.2 vs. urban). Property ownership was
also a protective factor for HSV-1 in women (OR 0.5, 95% CI 0.3–0.9
vs. non-owners). For analyses limited to men, risk factors included
current smoking (OR 3.7, 95% CI 1.5–9.2 vs. never smokers), age at
ﬁrst intercourse (OR 6.5, 95% CI 1.9–21.7 for 16 vs. 21 years),
total number of sex partners (OR 4.6, 95% CI 1.9–11.0 for 3+ vs. 1),
and occasional sex partners (OR 3.6, 95% CI 1.3–10.3 for 3+ vs. 0).
In a multivariate analysis, risk factors for HSV-2 seropositivity
(Table 4) were the same as those previously found in the age-,
recruitment site- and sex-adjusted analyses: age, female sex, lower
educational attainment, reporting a greater number of sexual
partners, and a reported history of genital herpes. Among males,
current smoking appeared to be associated with a lower risk of
HSV-2 seropositivity, and condom use did not appear to be
protective in either women or men. HSV-1 was also not associated
withHSV-2 in themultivariatemodel (OR 0.7, 95% CI 0.4–1.2) (data
not shown).
4. Discussion
This study is the ﬁrst, to our knowledge, to document the type-
speciﬁc HSV seroprevalence in Bucharest among both females and
males. HSV-1 seropositivity was consistently high across age and
sex, whereas HSV-2 seropositivity appeared to increase with age
and was generally higher in women than in men. A higher HSV-2
seropositivity overall was found among participants who reported
a previous history of genital herpes, a greater number of lifetime or
occasional sexual partners, and lower educational attainment. In
contrast, HSV-1 seropositivity was more strongly associated with
factors related to socio-economic status than HSV-2, including
rural residence, educational attainment, and home ownership.
Few data are currently available on HSV seroprevalence in
Eastern Europe. A multi-country study was conducted across
Europe and included data from the Czech Republic, Bulgaria, and
Slovenia using type-speciﬁc Focus Diagnostics HSV-1 and HSV-2
tests. HSV-2 seropositivity ranged from a low 6% among 3999
women aged >12 years in the Czech Republic to a high of 23.9% in
3200 women in Bulgaria,13 likely reﬂecting differences in sexual
behavior across geographical sites. An overall seroprevalence of
9.3% was found in a study of 2257 blood donors from four areas of
Poland.14 Thus, the HSV-2 seroprevalence of 15.2% in Bucharest
found in the present study falls within the Eastern European range,
and is also consistent with HSV-2 seroprevalence data from
Europe.13
In the same European multi-country study, HSV-1 seropreva-
lence appears to be higher in Eastern and Central Europe than
Western and Southern Europe.13 The 87% HSV-1 seropositivity
found in Romania is similar to the seroprevalence in equivalent age
groups of women surveyed in the Czech Republic, Bulgaria,
Slovenia, and Germany. The study across four regions of Poland
also found similar HSV-1 rates among those participants aged 15–
44 years, comparable to results from this Romanian study.14 The
HSV-1 seroprevalence found, although high, is similar to that found
in other developed countries, including Australia.15
Consistent with previous studies in Europe13,14 and the USA,1
women appeared to have a higher HSV-2 seropositivity than men.
Women may be more biologically susceptible to HSV infection, as
is the case for HIV infection.16 We found that HSV-1 seropositivity
was not associated with lower HSV-2 seropositivity in Bucharest,
Table 2
Odds ratios and 95% conﬁdence intervals for the association between HSV-2 seropositivity and sociodemographic and behavioral factors in adults aged 15–44 years in
Romaniaa
Factor All participants OR (95% CI) n Females OR (95% CI) n Males OR (95% CI)
Age (years)
15–19 1.0 (0.4–2.1) 100 1.0 (0.5–2.7) 50 -
20–24 1 152 1 57 1
25–29 1.5 (0.8–3.0) 157 1.7 (0.8–3.4) 54 0.5 (0.1–5.6)
30–34 2.9 (1.6–5.4) 153 2.5 (1.3–5.0) 49 5.3 (1.1–26)
35–39 2.8 (1.5–5.3) 152 2.6 (1.3–5.2) 52 4.1 (0.8–21.0)
40–44 6.6 (3.3–13.0) 47 5.7 (2.5–13.0) 47 8.9 (1.9–42.0)
p for trend <0.001 p for trend <0.001 p for trend <0.001
Education
Primary 2.3 (1.2–4.6) 82 2.9 (1.3–6.5) 49 1.1 (0.3–4.6)
Secondary 1.3 (0.9–2.0) 358 1.5 (1.0–2.4) 161 0.68 (0.3–1.6)
Higher 1 316 1 86 1
p for trend 0.020 p for trend 0.006 p for trend 0.74
Place of birth
Urban 1 246 1 618 1
Rural 1.2 (0.8–1.8) 51 1.3 (0.8–2.0) 143 0.63 (0.2–1.7)
Property owner
No 1 481 1 168 1
Yes 0.8 (0.6–1.2) 264 0.8 (0.5–1.3) 113 1.1 (0.4–2.9)
Marital status
Married 1 489 1 149 1
Cohabitating 1.7 (1.1–2.6) 138 1.9 (1.1–3.2) 32 1.1 (0.3–4.3)
Single/divorced 1.2 (0.6–2.0) 132 1.4 (0.8–2.7) 110 0.8 (0.2–3.9)
Smoking status
Never 1 352 1 97 1
Former smoker 1.2 (0.8–1.7) 227 1.2 (0.8–1.9) 91 0.74 (0.3–1.8)
Present smoker 1.3 (0.8–2.0) 180 1.6 (1.0–2.5) 107 0.5 (0.2–1.4)
Age at ﬁrst intercourse (years)
16 2.6 (1.3–5.1) 77 2.6 (1.1–6.0) 103 3.5 (0.7–18)
17–18 2.3 (1.4–3.9) 202 2.0 (1.2–3.5) 90 4.1 (0.8–20)
19–20 1.6 (1.0–2.7) 226 1.6 (0.9–2.9) 48 2.2 (0.4–12)
21+ 1 212 1 28 1
p for trend 0.001 p for trend 0.005 p for trend 0.107
Total number of sexual partners
0–1 1 400 1 53 1
2 2.1 (1.3–3.2) 264 2.2 (1.4–3.5) 76 1.0 (0.2–6.2)
3+ 3.5 (2.1–5.9) 94 3.1 (1.7–5.4) 164 3.7 (0.8–17)
p for trend 0.000 p for trend 0.000 p for trend 0.018
Partner had other sexual partners (ever)
No 1 276 1 148 1
Don’t know 1.6 (0.8–1.7) 292 1.8 (1.0–3.1) 106 0.5 (0.1–4.0)
Yes 1.9 (1.3–2.8) 142 2.1 (1.3–3.4) 19 1.2 (0.5–2.7)
Occasional sex partner
0 1 366 1 35 1
1–2 1.3 (0.7–2.1) 135 1.5 (0.9–2.5) 63 0.9 (0.1–6.7)
3+ 1.9 (1.1–3.3) 47 2.5 (1.2–5.2) 139 3.9 (0.8–19)
p for trend 0.023 p for trend 0.012 p for trend 0.026
Condom use with occasional partner
No 1 48 1 26 1
Yes 1.4 (0.6–3.4) 67 1.4 (0.5–4.2) 127 1.2 (0.2–5.7)
Ever use condoms
No 1 479 1 136 1
Yes 0.8 (0.5–1.1) 282 0.8 (0.5–1.2) 161 0.7 (0.3–1.5)
Oral contraceptive use
No 1 498 1 259 1
Yes 0.8 (0.6–1.3) 263 0.9 (0.6–1.4) 0 -
Any STI history
No 1 528 1 203 1
Yes 2.1 (1.3–3.1) 127 1.9 (1.2–3.0) 49 2.2 (0.9–5.5)
Genital herpes history
No 1 605 1 231 1
Don’t know 2.2 (1.4–3.4) 104 2.6 (1.6–4.3) 44 1.0 (0.3–3.3)
Yes 7.1 (4.2–12.1) 52 7.2 (3.8–13) 22 5.2 (1.8–15)
HSV, herpes simplex virus; OR, odds ratio; CI, conﬁdence interval; STI, sexually transmitted infection.
a OR = odds ratios adjusted for age, recruitment site and, where appropriate, sex.
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The cross-sectional design of the current analyses limited our
ability to investigate potential temporal relationships between
HSV-2 and HSV-1 infections.
We found a notably higher HSV-2 seroprevalence among
participants from Bucharest reporting lower rather than highereducational attainment. Study participants reporting a primary
school level of education were more likely to report younger age at
ﬁrst intercourse (median 16 years for primary vs. 18.5 years for
secondary) and less regular use of condoms with regular or
occasional sexual partners (28% and 42% for primary, respectively
vs. 53% and 82% for higher education, respectively). In contrast,
Table 3
Odds ratios and 95% conﬁdence intervals for the association between HSV-1 seropositivity and sociodemographic and behavioral factors in adults aged 15–44 years in
Romaniaa
Factor All participants OR (95% CI) n Females OR (95% CI) n Males OR (95% CI)
Age (years)
15–19 1 100 1 50 1
20–24 0.7 (0.4–1.3) 152 0.7 (0.3–1.5) 57 0.7 (0.3–2.1)
25–29 1.0 (0.5–2.9) 157 1.0 (0.4–2.3) 54 0.9 (0.3–2.4)
30–34 0.7 (0.4–1.4) 153 0.6 (0.3–1.4) 49 1.0 (0.3–2.8)
35–39 1.2 (0.6–2.4) 152 0.9 (0.4–2.1) 52 2.8 (0.7–11)
40–44 1.3 (0.6–3.1) 47 1.5 (0.4–6.0) 47 1.3 (0.4–4.1)
p for trend 0.26 p for trend 0.38 p for trend 0.17
Education
Primary 2.3 (1.1–4.9) 82 1.9 (0.8–4.8) 49 2.1 (0.5–8.0)
Secondary 1.8 (1.2–2.8) 358 2.8 (1.6–4.6) 161 0.7 (0.3–1.6)
Higher 1 316 1 86 1
p for trend 0.003 p for trend 0.002 p for trend 0.50
Place of birth
Urban 1 246 1 618 1
Rural 2.4 (1.3–4.5) 51 2.4 (1.1–5.2) 143 2.1 (0.7–6.7)
p for trend 0.008 p for trend 0.024 p for trend 0.19
Property owner
No 1 264 1 113 1
Yes 0.7 (0.4–1.0) 481 0.5 (0.3–0.9) 168 1.0 (0.5–2.1)
p for trend 0.050 p for trend 0.019 p for trend 0.99
Marital status
Married 1 489 1 149 1
Cohabitating 1.5 (0.8–2.6) 138 1.3 (0.7–2.4) 32 4.8 (0.6–40)
Single/divorced 0.8 (0.5–1.5) 132 1.4 (0.6–3.0) 110 0.51 (0.2–1.5)
p for trend 0.67 p for trend 0.38 p for trend 0.17
Smoking status
Never 1 352 1 97 1
Former smoker 1.0 (0.7–1.5) 227 0.8 (0.5–1.3) 91 1.6 (0.7–3.4)
Present smoker 1.6 (1.0–2.6) 180 1.0 (0.6–1.9) 107 3.7 (1.5–9.2)
p for trend 0.085 p for trend 0.91 p for trend 0.004
Age at ﬁrst intercourse(years)
16 3.0 (1.4–6.5) 77 2.2 (0.7–6.7) 103 6.5 (1.9–21.7)
17–18 1.3 (0.8–2.2) 202 1.0 (0.5–1.7) 90 3.7 (1.2–11)
19–20 1.2 (0.7–1.9) 226 1.1 (0.6–1.9) 48 1.9 (0.6–5.5)
21+ 1 212 1 28 1
p for trend 0.016 p for trend 0.50 p for trend 0.001
Total number of sex partners
1 1 400 1 53 1
2 0.9 (0.6–1.4) 264 0.8 (0.5–1.3) 76 1.4 (0.6–3.3)
3+ 2.1 (1.2–3.7) 94 1.1 (0.5–2.3) 164 4.6 (1.9–11.0)
p for trend 0.043 p for trend 0.85 p for trend 0.000
Partner had other sexual partners (ever)
No 1 276 1 148 1
Don’t know 1.5 (1.0–2.3) 292 1.3 (0.8–2.2) 106 2.5 (1.1–5.6)
Yes 0.8 (0.5–1.4) 142 0.8 (0.5–1.5) 19 0.6 (0.2–1.8)
Occasional sex partner
0 1 366 1 35 1
1–2 1.0 (0.6–1.6) 135 1.1 (0.6–2.1) 63 0.9 (0.3–2.4)
3+ 2.4 (1.2–4.8) 47 1.0 (0.4–2.6) 139 3.6 (1.3–10.3)
p for trend 0.033 p for trend 0.81 p for trend 0.003
Condom use with occasional partner
No 1 48 1 26 1
Yes 0.4 (0.1–1.2) 67 0.4 (0.1–2.0) 127 0.4 (0. 1–1.9)
Any STI history
No 1 528 1 203 1
Yes 1.3 (0.8–2.2) 127 1.1 (0.6–2.0) 49 1.9 (0.7–5.4)
p for trend 0.35 p for trend 0.79 p for trend 0.20
Genital herpes history
No 1 605 1 231 1
Don’t know 1.3 (0.7–2.2) 104 1.0 (0.5–2.0) 44 1.8 (0.6–5.5)
Yes 0.6 (0.3–1.2) 52 0.5 (0.2–1.0) 22 1.1 (0.3–1.2)
HSV, herpes simplex virus; OR, odds ratio; CI, conﬁdence interval; STI, sexually transmitted infection.
a OR = odds ratios adjusted for age, recruitment site and, where appropriate, sex.
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fewer lifetime sexual partners than those with higher educational
attainment (1 for primary vs. 2 for university). We do not have
information concerning potential differences in the sexual risk
proﬁles of participant’s chosen sexual partners with lower vs.
higher educational attainment, although network analyses would
have proven useful.18Among study strengths, a well validated serological assay
(HerpeSelect)19 was used for the determination of type-speciﬁc
serological antibodies in a central laboratory, with high quality
control standards. The inclusion of men in addition to women
allowed for the comparison of a wide range of risk factors by sex.
Limitations include the relatively small sample size of 297 men,
which limited our ability to clearly determine HSV-2 risk factors,
Table 4
Results of the multivariate analysis by risk factors for HSV-2 seropositivity in male and female adults aged 15–44 years in Bucharest, Romaniaa,b
Factor All subjects OR (95% CI) n Females OR (95% CI) n Males OR (95% CI)
Sex
Female 1 - -
Male 0.3 (0.2–0.7) - -
Age (years)
15–19 0.7 (0.3–2.0) 100 0.8 (0.3–2.4) 50 -
20–24 1 152 1 57 1
25–29 1.2 (0.5–2.7) 157 1.2 (0.5–2.9) 54 0.5 (0.1–8.9)
30–34 2.6 (1.3–5.5) 153 2.4 (1.1–5.4) 49 6.1 (0.9–40)
35–39 2.2 (1.0–4.7) 152 1.8 (0.8–4.1) 52 7.6 (1.0–57)
40–44 4.3 (1.7–11) 47 2.8 (0.8–10) 47 11 (1.7–78)
p for trend < 0.001 p for trend 0.019 p for trend < 0.001
Education
Primary 5.2 (2.0–13) 82 4.7 (1.5–14) 49 10 (1.2–91)
Secondary 1.8 (1.1–3.0) 358 1.9 (1.0–3.5) 161 0.37 (0.1–1.1)
Higher 1 316 1 86 1
p for trend 0.001 p for trend 0.004 p for trend 0.052
Smoking status
Never 1 352 1 97 1
Former smoker 0.8 (0.5–1.5) 227 1.2 (0.6–2.4) 91 0.2 (0.1–0.9)
Present smoker 0.9 (0.5–1.5) 180 1.1 (0.6–2.0) 107 0.2 (0.1–0.7)
Age at ﬁrst intercourse (years)
16 1.0 (0.4–2.5) 77 1.1 (0.3–3.3) 103 0.7 (0.1–5.4)
17–18 1.7 (0.9–3.4) 202 1.5 (0.7–3.2) 90 2.3 (0.3–15)
19–20 1.4 (0.7–2.6) 226 1.4 (0.7–2.7) 48 1.2 (0.2–8.9)
21+ 1 212 1 28 1
p for trend 0.521 p for trend 0.508 p for trend 0.642
Total number of sex partners
0–1 1 400 1 53 1
2 2.0 (1.0–3.8) 264 2.1 (1.0–4.2) 76 0.2 (0.1–8.3)
3+ 2.8 (1.1–7.2) 94 2.7 (0.9–7.8) 164 0.5 (0.1–23)
p for trend 0.023 p for trend 0.038 p for trend 0.771
Occasional sex partners
0 1 366 1 35 1
1–2 0.8 (0.4–1.5) 135 0.8 (0.4–1.6) 63 3.2 (0.2–67)
3+ 1.8 (0.7–4.6) 47 1.6 (0.5–4.8) 139 10 (0.5–221)
p for trend 0.443 p for trend 0.834 p for trend 0.096
Ever use condoms
No 1 479 1 136 1
Yes 0.7 (0.43–1.1) 282 0.8 (0.4–1.3) 161 0.4 (0.1–1.1)
Genital herpes history
No 1 605 1 231 1
Don’t know 2.3 (1.3–4.0) 104 3.0 (1.6–5.7) 44 0.7 (0.2–3.8)
Yes 6.1 (3.1–12) 52 5.5 (2.5–12) 22 7.5 (1.9–30)
HSV, herpes simplex virus; OR, odds ratio; CI, conﬁdence interval; STI, sexually transmitted infection.
a OR = odds ratios adjusted for all other variables in the table.
b Results are adjusted for recruitment site.
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Another limitation is that the HerpeSelect HSV-1 ELISA may have
been less speciﬁc for the detection of type-speciﬁc HSV-1
antibodies as compared to the speciﬁcity of the HerpeSelect
HSV-2 ELISA test for the detection of type-speciﬁc HSV-2
antibodies.19
Furthermore, sample representativenessmay have been reduced
by the exclusion of those with recurrent HSV-1/2 infections or other
symptomatic STIs. We should emphasize that this is a convenience
sample; although this study was conducted at two hospitals in
Bucharest with wide catchment areas, HSV-2 and HSV-1 seropreva-
lence ﬁgures may not be representative of the general Romanian
population of reproductive age. It is also possible that the
participants enrolled at the infectious diseases institute were more
likely tohavebeenexposed toan infectiousdisease such asHSV, thus
may have been expected to have a higher seroprevalence than at the
university hospital. We believe, however, that this did not represent
an important bias, given that HSV-2 seroprevalence was similar
among participating women from these two clinic sites. The
selection criteria used in this study excluded individuals who
reported recurrent labial andgenital herpes aswell as a symptomatic
STD or AIDS. These enrollment criteria potentially excluded a
proportion of the population who may have been more likely to beHSV-2-seropositive, resulting in a potential underestimation of the
overall HSV seroprevalence in our survey sample. Representative-
ness could be increased by examining HSV seroprevalence in other
geographical areas of Romania, and by including populations that
may not seek clinical care at hospitals, such as potentially vulnerable
subgroups within Romania.20 A sub-analysis among ethnic sub-
groups found higher HSV-2 seroprevalence amongst 21 Roma (19%)
vs. 1032 ethnic Romanians (15.2%), although associations were not
signiﬁcant due to the limited sample size.
Longitudinal studies in Romania could potentially provide
valuable information on HSV-2 epidemiology over time, particu-
larly as HSV-2 seropositivity is a relatively reliable marker of
higher risk sexual behavior within a population.21 Once high-risk
HSV-2-seropositive population groups are detected, long-term
sexual risk prevention interventions could be established to reduce
the spread of HSV-2, as well as other STIs such as HIV.22
Our results of HSV seroprevalence in Bucharest, Romania
should be viewed in the context of rates of other STIs at the
country-level. Although rates of HIV (0.93/100 000 population in
2006)23 and Chlamydia trachomatis (1.1/100 000 in 2006)23 remain
relatively low, the incidence of invasive cervical cancer is amongst
the highest reported in Europe (23.4/100 000 women in 2002),24
likely attributable to a relatively lower coverage of regular
V. Arama et al. / International Journal of Infectious Diseases 14S (2010) e25–e31 e31cytological screening services. In 2006, rates of syphilis (6.2/100
000) and gonorrhea (26/100 000) were similar to those in other
Eastern and Western European countries.23 With the recent entry
of Romania into the European Union,25 socio-economic changes25
could lead to higher levels of risky sexual behavior and
corresponding higher rates of HSV-2 and other STIs. Monitoring
HSV-2 seroprevalence could assist in mapping changes in sexual
behavior in these times of social and economic change.
Acknowledgements
The authors would like to thank Mrs Jane Markley-Papadaki of
Focus Diagnostics for assisting in the initiation and monitoring of
this study,MsVirginia Guidrey andMs ThuNguyen for their help in
manuscript preparation, as well as Mrs Helen Kehayia for her
technical assistance.
Conﬂict of interest: This study was funded by GlaxoSmithKline
Research and Development. JMP is a full-time employee of GSK. JSS
has received research grants or contracts, honoraria and consulting
feesduringthe last fouryears fromGlaxoSmithKline(GSK)andFocus
Diagnostics.Allotherauthorshavenocompetinginterests todeclare.
References
1. Smith JS, Robinson NJ. Age-speciﬁc prevalence of infection with herpes simplex
virus types 2 and 1: a global review. J Infect Dis 2002;186(Suppl 1):S3–8.
2. Celum CL. The interaction between herpes simplex virus and human immuno-
deﬁciency virus. Herpes 2004;11(Suppl 1):A36–45.
3. Mbopi-Keou FX, Gresenguet G, Mayaud P. Interactions between herpes simplex
virus type 2 and human immunodeﬁciency virus type 1 infection in African
women: opportunities for intervention. J Infect Dis 2000;82:1090–6.
4. Tao G, Kassler WJ, Rein DB. Medical care expenditures for genital herpes in the
United States. Sex Transm Dis 2000;27:32–8.
5. Aurelian L. Herpes simplex virus (Herpesviridae). General features. In: Granoff
A, Webster RG, editors. Encyclopedia of virology. London: Academic Press; 1999.
p. 677–86.
6. Ashley RL, Wald A. Genital herpes: of the epidemic and potential use of type-
speciﬁc serology. Clin Microbiol Rev 1999;12:1–8.
7. Nahnias AJ, Lee FK, Beckman-Nahnias S. Sero-epidemiological and sociological
patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl
1990;69:19–36.
8. Fleming D, McQuillan G, Johnson R. Herpes simplex virus type 2 in the United
States, 1976 to 1994. N Engl J Med 1997;337:1105–11.9. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes
simplex virus 2 shedding in immunocompetent women. Effect of acyclovir
treatment. J Clin Invest 1997;99:1092–7.
10. Cusini M, Ghislanzoni M. The importance of diagnosing genital herpes. J
Antimicrob Chemother 2001;47(Suppl T1):9–16.
11. Romanian statistical yearbook. Romania: National Institute of Statistics; 2007.
Available at: http://www.insse.ro. (accessed November 2009)
12. Smith JS, Bailey RC, Westreich DJ, Maclean I, Agot K, Ndinya-Achola JO, et al.
Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya,
using the HerpeSelect ELISA, Kalon ELISA, Western blot and inhibition testing.
Sex Transm Infect 2009;85:92–6.
13. Pebody RG, Andrews N, Brown D, Gopal R, De Melker H, Franc¸ois G, et al. The
seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sex Transm
Infect 2004;80:185–91.
14. Smith JS, Rosinska M, Trzcinska A, Pimenta JM, Litwinska B, Siennicka J. Type
speciﬁc seroprevalence of HSV-1 and HSV-2 in four geographical regions of
Poland. Sex Transm Infect 2006;82:159–63.
15. Cunningham AL, Taylor R, Taylor J, Marks C, Shaw J, Mindel A. Prevalence of
infection with herpes simplex virus types 1 and 2 in Australia: a nationwide
population based survey. Sex Transm Infect 2006;82:164–8.
16. Burger H, Weiser B. Biology of HIV-1 in women and men. Clin Obstet Gynecol
2001;44:137–43.
17. Looker KJ, Garnett GP. A systematic review of the epidemiology and interaction
of herpes simplex virus types 1 and 2. Sex Transm Infect 2005;81:103–7.
18. De Rubeis E, Wylie JL, Cameron DW, Nair RC, Jolly AM. Combining social
network analysis and cluster analysis to identify sexual network types. Int J
STD AIDS 2007;18:754–9.
19. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of
focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies
among women in ten diverse geographical locations. Clin Microbiol Infect
2004;10:530–6.
20. Kabakchieva E, Amirkhanian YA, Kelly JA, McAuliffe TL, Vassileva S. High levels
of sexual HIV/STD risk behaviour among Roma (Gypsy) men in Bulgaria:
patterns and predictors of risk in a representative community sample. Int J
STD AIDS 2002;13:184–91.
21. Gutierrez JP, Conde-Gonza´lez CJ,Walker DM, Bertozzi SM. Herpes simplex virus
type 2 among Mexican high school adolescents: prevalence and association
with community characteristics. Arch Med Res 2007;38:774–82.
22. DobbsME, Strasser JE, Chu CF, Chalk C,Milligan GN. Clearance of herpes simplex
virus type 2 by CD8+ T cells requires gamma interferon and either perforin- or
Fas-mediated cytolytic mechanisms. J Virol 2005;79:14546–54.
23. Centralized Information System for Infectious Diseases (CISID). World Health
Organization Regional Ofﬁce for Europe. Available at: http://data.euro.who.int/
cisid/ (accessed November 2007)
24. Ferlay J, Bray F, Pisani P, Parkin DM., GLOBOCAN 2002: Cancer incidence,
mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. Lyon:
IARCPress; 2004.
25. European Union. Enlargement 2004 and 2007. Available at: http://europa.eu/
legislation_summaries/enlargement/2004_and_2007_enlargement/index_en.
htm (accessed January 2008)
